Clozapine vs Risperidone (Rykindo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Clozapine

Marketed by HLS Therapeutics Inc.

Approved in Schizophreniasmall molecule
Weak signal

NCT00250575 · Phase 3 · completed

The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.

Next expected readout: April 2027 · NCT04580134 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)

Result source: NCT03510325

Risperidone (Rykindo)

Marketed by Luye Pharma Group

Approved in Schizophreniasmall molecule
Weak signal

NCT02055287 · Phase 1 · completed

A non-randomized, open-label, four-dose pharmacokinetic study of Rykindo in 36 participants. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointClozapineRisperidone (Rykindo)
PANSS total, change—Not posted · NCT00649844—Not posted · NCT00216580
CGI-S, change—Not posted · NCT00649844—Not posted · NCT00216580
PANSS response—Not posted · NCT00649844—Not posted · NCT00216580
PSP, change—Not posted · NCT00649844—Not posted · NCT00216580
Relapse (% of patients)—Not posted · NCT00649844—Not posted · NCT00216580

PANSS total, change

Clozapine
—Not posted · NCT00649844
Risperidone (Rykindo)
—Not posted · NCT00216580

CGI-S, change

Clozapine
—Not posted · NCT00649844
Risperidone (Rykindo)
—Not posted · NCT00216580

PANSS response

Clozapine
—Not posted · NCT00649844
Risperidone (Rykindo)
—Not posted · NCT00216580

PSP, change

Clozapine
—Not posted · NCT00649844
Risperidone (Rykindo)
—Not posted · NCT00216580

Relapse (% of patients)

Clozapine
—Not posted · NCT00649844
Risperidone (Rykindo)
—Not posted · NCT00216580
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Risperidone (Rykindo): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clozapine: 3 of 4 rows · Risperidone (Rykindo): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClozapine
Dropout rate
41.7%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT00498550 · Phase 4 · registry result, not featured evidence
17.2%
NCT02404155 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT00498550 · Phase 4 · registry result, not featured evidence
—
NCT02404155 · Phase na · registry result, not featured evidence
Serious AEs
13%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
26.7%
NCT00498550 · Phase 4 · registry result, not featured evidence
6.9%
NCT02404155 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
other-sialorrhea 43.5%
weight gain 30.4%
sedation 21.7%
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
gastrointestinal disorder - other: hypersalivation 66.7%
somnolence 60%
weight gain 40%
NCT00498550 · Phase 4 · registry result, not featured evidence
salivation 68.2%
sedation 52.9%
malaise 52.6%
NCT02404155 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clozapine

Cannabis Use Intensity Joints Per 2.36 vs 2.35 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 10.21 weeks as posted
Cannabis Use Frequency Days Per 0.14 vs 0.15 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 4.26 days as posted
Cannabis Use Joints Per 0.02 per week
absolute value · per week
No placebo or comparator arm
NCT00498550 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Risperidone (Rykindo)'s landscape